NasdaqGS:REGNBiotechs
Regeneron (REGN) Stock Looks Undervalued Despite A 28% Gain And Legal Risk
Regeneron Pharmaceuticals has delivered a 28.2% return over the past year, yet its valuation checks still lean toward the stock looking inexpensive rather than stretched. That sits against a backdrop of mixed sentiment, with recent legal action around a failed melanoma trial raising questions about how much risk is already reflected in the current share price.
Regeneron Pharmaceuticals is up 28.2% over the past year, which puts recent shareholders in profit and is prompting closer scrutiny...